A Phase 3 interventional study of Macitentan and Tadalafil in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 58 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 3, and was the 4th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 9th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2016, is one of 31 in phase 3, and was the 44th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RHC performed between Day -28 and Day 1, meeting all the following criteria:
Symptomatic PAH belonging to one of the following subgroups:
Exclusion Criteria:
Presence of three or more of the following risk factors for heart failure with preserved at screening:
Coronary artery disease, i.e., any of the following:
Presence of one or more of the following signs of relevant lung disease at any time up to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Macitentan, tadalafil, and selexipag
Drug: Macitentan · Drug: Tadalafil · Drug: Selexipag
Macitentan, tadalafil, and placebo
Drug: Macitentan · Drug: Tadalafil
Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)
Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD)
The change from baseline to Week 26 in 6MWD was calculated as Week 26 minus baseline. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels
The change from baseline to Week 26 in NT-proBNP was expressed as the ratio of Week 26 to baseline NT-proBNP (Week 26 divided by baseline). A geometric least square mean ratio of Week 26 to baseline NT-proBNP \<1 corresponds to a reduction in NT-proBNP from baseline. Missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC)
WHO FC is a classification graded from Class I to IV which reflects disease severity based on symptoms. Worsening was defined as death or hospitalization due to PAH. Class I: No limitation of activity; Class II: slight limitation with ordinary activities; Class III: may not have symptoms at rest but greatly limited activities; Class IV: symptoms at rest and inability to carry out any physical activity without symptoms. Missing values were imputed using a LOCF approach.
Time frame: Week 26
Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP)
Change from baseline to Week 26 in mean Pulmonary Arterial Pressure (mPAP) was measured. The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP)
Change from baseline to Week 26 in mean Right Atrial Pressure (mRAP) was measured. Missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Total Pulmonary Resistance
Change from baseline to Week 26 in total pulmonary resistance was measured. Total pulmonary resistance was calculated as mPAP/CO\*80, where CO is cardiac output. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Cardiac Index
Change from baseline to Week 26 in cardiac index was measured. Cardiac index is the amount of blood pumped by the heart, per minute, per meter square of body surface area. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Venous Oxygen Saturation (%)
Change from baseline to Week 26 in venous oxygen saturation was measured. Missing values were imputed using a LOCF approach.
Time frame: Baseline, Week 26
Number of Participants With Disease Progression Event
Number of participants with disease progression event were reported. Disease progression event as adjudicated by the CEC, defined as any of the following: a. Death (all causes; adjudicated for PAH relationship); b. Hospitalization for worsening PAH; c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH; d. Clinical worsening defined as a post-baseline decrease in 6MWD by more than (\>) 15 percent (%) from the highest 6MWD obtained at or after baseline, accompanied by WHO FC III or IV (both conditions confirmed at two consecutive post-baseline visits separated by 1-21 days).
Time frame: Week 26, Month 12, Month 18, Month 24, Month 30, and End of Analysis Period (up to 40 months)
| Milestone | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Started | 123 | 124 |
| Treated | 123 | 123 |
| Completed | 98 | 98 |
| Not completed | 25 | 26 |
| Withdrew: Death | 4 | 12 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Withdrawal by subject | 7 | 4 |
| Withdrew: Physician decision | 7 | 5 |
| Withdrew: Sponsor decision | 0 | 1 |
Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach.
| ratio | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) | 0.46 (0.422 to 0.503) | 0.48 (0.441 to 0.526) |
The change from baseline to Week 26 in 6MWD was calculated as Week 26 minus baseline. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Missing values were imputed using a LOCF approach.
| meter | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) | 54.96 (40.419 to 69.501) | 56.39 (41.447 to 71.327) |
The change from baseline to Week 26 in NT-proBNP was expressed as the ratio of Week 26 to baseline NT-proBNP (Week 26 divided by baseline). A geometric least square mean ratio of Week 26 to baseline NT-proBNP \<1 corresponds to a reduction in NT-proBNP from baseline. Missing values were imputed using a LOCF approach.
| ratio | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels | 0.26 (0.206 to 0.328) | 0.25 (0.200 to 0.320) |
WHO FC is a classification graded from Class I to IV which reflects disease severity based on symptoms. Worsening was defined as death or hospitalization due to PAH. Class I: No limitation of activity; Class II: slight limitation with ordinary activities; Class III: may not have symptoms at rest but greatly limited activities; Class IV: symptoms at rest and inability to carry out any physical activity without symptoms. Missing values were imputed using a LOCF approach.
| percentage of participants | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC) | 99.2 | 97.5 |
Change from baseline to Week 26 in mean Pulmonary Arterial Pressure (mPAP) was measured. The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Missing values were imputed using a LOCF approach.
| millimeters of mercury (mmHg) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP) | -12.92 (-14.609 to -11.235) | -12.20 (-13.881 to -10.515) |
Change from baseline to Week 26 in mean Right Atrial Pressure (mRAP) was measured. Missing values were imputed using a LOCF approach.
| mmHg | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP) | -1.78 (-2.512 to -1.045) | -1.69 (-2.429 to -0.955) |
Change from baseline to Week 26 in total pulmonary resistance was measured. Total pulmonary resistance was calculated as mPAP/CO\*80, where CO is cardiac output. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.
| dynes*second per centimeter^5 | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Total Pulmonary Resistance | -511.88 (-569.36 to -454.40) | -514.28 (-571.45 to -457.11) |
Change from baseline to Week 26 in cardiac index was measured. Cardiac index is the amount of blood pumped by the heart, per minute, per meter square of body surface area. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.
| liters per minute per meter square | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Cardiac Index | 0.97 (0.814 to 1.130) | 0.84 (0.684 to 0.997) |
Change from baseline to Week 26 in venous oxygen saturation was measured. Missing values were imputed using a LOCF approach.
| percentage of oxygen saturation | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Change From Baseline to Week 26 in Venous Oxygen Saturation (%) | 5.59 (4.370 to 6.801) | 6.79 (5.561 to 8.020) |
Number of participants with disease progression event were reported. Disease progression event as adjudicated by the CEC, defined as any of the following: a. Death (all causes; adjudicated for PAH relationship); b. Hospitalization for worsening PAH; c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH; d. Clinical worsening defined as a post-baseline decrease in 6MWD by more than (\>) 15 percent (%) from the highest 6MWD obtained at or after baseline, accompanied by WHO FC III or IV (both conditions confirmed at two consecutive post-baseline visits separated by 1-21 days).
| Participants | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| Week 26 | 8 | 13 |
| Month 12 | 13 | 20 |
| Month 18 | 15 | 23 |
| Month 24 | 15 | 25 |
| Month 30 | 16 | 27 |
| End of Analysis Period (up to 40 months) | 16 | 27 |
Collected over Up to 42 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 4/119 (3.4%) | 58/119 (48.7%) | 118/119 (99.2%) |
| Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 12/127 (9.4%) | 48/127 (37.8%) | 119/127 (93.7%) |
| Event | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| PneumoniaInfections and infestations | 8/119 | 4/127 |
| Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders | 8/119 | 8/127 |
| Right Ventricular FailureCardiac disorders | 6/119 | 8/127 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 6/119 | 5/127 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 6/119 | 1/127 |
| SyncopeNervous system disorders | 0/119 | 6/127 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/119 | 0/127 |
| SepsisInfections and infestations | 4/119 | 3/127 |
| AnaemiaBlood and lymphatic system disorders | 3/119 | 2/127 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 3/119 | 1/127 |
| Event | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) |
|---|---|---|
| HeadacheNervous system disorders | 83/119 | 78/127 |
| DiarrhoeaGastrointestinal disorders | 66/119 | 41/127 |
| NauseaGastrointestinal disorders | 56/119 | 33/127 |
| Oedema PeripheralGeneral disorders | 45/119 | 46/127 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 37/119 | 24/127 |
| Pain in JawMusculoskeletal and connective tissue disorders | 35/119 | 15/127 |
| VomitingGastrointestinal disorders | 30/119 | 14/127 |
| DyspepsiaGastrointestinal disorders | 27/119 | 17/127 |
| DizzinessNervous system disorders | 17/119 | 27/127 |
| FatigueGeneral disorders | 24/119 | 22/127 |
Full Analysis Set (FAS) includes all randomized participants.
| Age, Continuous(years) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Total |
|---|---|---|---|
| Mean | 52.2 ± 13.48 | 51.6 ± 13.92 | 51.9 ± 13.67 |
| Sex: Female, Male(Participants) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Total |
|---|---|---|---|
| Female | 93 | 94 | 187 |
| Male | 30 | 30 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 10 | 20 |
| Not Hispanic or Latino | 106 | 108 | 214 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Race/Ethnicity, Customized(participants) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Total |
|---|---|---|---|
| Black or African American | 5 | 5 | 10 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Asian | 7 | 3 | 10 |
| White | 102 | 108 | 210 |
| Other | 3 | 3 | 6 |
| Unknown or Not Reported | 5 | 5 | 10 |
| Region of Enrollment(participants) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Total |
|---|---|---|---|
| AUSTRALIA | 2 | 2 | 4 |
| AUSTRIA | 9 | 5 | 14 |
| BELGIUM | 2 | 5 | 7 |
| CANADA | 11 | 14 | 25 |
| DENMARK | 3 | 2 | 5 |
| FRANCE | 4 | 5 | 9 |
| GERMANY | 13 | 23 | 36 |
| IRELAND | 1 | 0 | 1 |
| ITALY | 5 | 6 | 11 |
| NETHERLANDS | 2 | 2 | 4 |
| SPAIN | 2 | 1 | 3 |
| SWEDEN | 7 | 0 | 7 |
| SWITZERLAND | 1 | 1 | 2 |
| UNITED KINGDOM | 3 | 2 | 5 |
| UNITED STATES | 58 | 56 | 114 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Aug 2019, 39 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 39 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →